Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Q1 FY2026 Earnings Presentation
30 slides from Mankind Pharma's earnings presentation, Jul 31, 2025
Slide 1: Stock exchange cover letter for investor presentation
July 31, 2025 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Investor Presentation Pursuant to Regulation 30
Slide 2: Investor Presentation Q1 FY26
ig Mankindil> INVESTOR PRESENTATION QI FY26 July, 2025
Slide 3: Index
Index 03 Additional Information • Mankind Pharma at a Glance (FY25) • Key Milestones • BSV at a Glance (FY25) • Expansion in Specialty and Super Specialty 01 Financial Performance Segments • Key Financials – Q1 FY26 • Key Strengths • P & L Highlights – Q1 FY26 • Strategy Going Ahead • Key Financial
Slide 4: Financial Performance
ig Mankindii> Sirois Life Financial Performance
Slide 5: Q1 FY26 - Key Financial Snapshot
Q1 FY26 - Key Financial Snapshot Financials / Margins Growth Capital Efficiency 11% / 42% 3,570 24.5% ROCE / Adj. ROCE1 Revenue (INR Cr) YoY Growth 5,249 Net Debt (INR Cr) 850 / 23.8% 25.8% EBITDA (INR Cr) / Margin YoY Growth 1.6x Net Debt / EBITDA Mr. Rajeev Juneja Vice Chairman & Managing Director
Slide 6: Q1 FY26 - P&L Highlights
Q1 FY26 - P&L Highlights1 INR Cr Q1FY26 Q1FY25 YoY Growth Q4FY25 QoQ Growth Revenue from Operations (A=B+C) 3,570 2,868 24.5% 3,079 15.9% Domestic Business (B) 3,101 2,609 18.9% 2,544 21.9% i. Domestic Business (ex CH) 2,864 2,403 19.2% 2,366 21.0% ii. Consumer Healthcare (CH) 237 206 15.0% 178 33.1
Slide 7: Key Financial Metrics
Key Financial Metrics1 Cash Flow from Operations (INR Cr) CAPEX (INR Cr) ROCE2 CFO to CAPEX as 84% 80% 81% 99% 3.8% 4.3% 4.4% 3.6% EBITDA % of Rev With BSV With BSV 531 Acquisition Acquisition 2,413 2,152 389 40% 42% 34% 34% 840 546 125 127 11%* 11%* FY24 FY25 Q1FY25 Q1FY26 FY24 FY25 Q1FY25 Q1FY26 M
Slide 8: Business Updates
ig Mankindil> Jeroing Life Business Updates
Slide 9: Domestic Business Performance
Domestic Business Performance Strong Growth in Domestic Revenue1,2 INR Cr 10,675 9,447 8,453 3,101 2,609 FY23 FY24 FY25 Q1FY25 Q1FY26 Domestic revenue2 increased by 19% YoY driven by steady growth in base business and BSV consolidation Market share3 increased from 4.8% in Mar-25 to 4.9% as of Ju
Slide 10: Increased chronic share in Q1FY26
Increased chronic share by 194 bps* in Q1FY26 Consistent focus to increase chronic contribution BSV’s super specialty portfolio Mankind Consolidated 38.3 39.0 39.3 40.0 37.6 36.8 40.0 40.0 34.0 35.4 35.0 39.0 39.3 38.8 37.6 38.3 39.0 39.3 32.7 38.3 37.6 37.1 36.9 35.6 34.1 17.4 15.4 14.4 14.4 14.1 F
Slide 11: Q1 FY26 – Therapy wise Performance
Q1 FY26 – Therapy wise Performance High Ranks across Acute and Chronic Areas Q1FY26 - Sales Mix representing Diversified Therapy Presence Rank in FY 21-25 CAGR 2% MS% Key Therapy Areas CVM 11% (Q1FY26) 16% (Q1FY26) Mankind IPM Cardiovascular Anti-Infectives 4% Chronic therapies 3 4.5% 13% 10% Gynaec
Slide 12: Consumer Healthcare – WOS of Mankind Pharma
Consumer Healthcare – WOS1 of Mankind Pharma Consumer Healthcare Segment Revenue (INR Cr) EBITDA % 19.9% 19.0% 19.5% 18.0% 809 692 706 206 237 FY23 FY24 FY25 Q1FY25 Q1FY26 Strong revenue growth of 15% YoY in Q1FY26 led by steady growth across all key brands MT & E-Com share increased to 11% in Q
Slide 13: Strong Corporate Identity Complements Brand Recall
Strong Corporate Identity Complements Brand Recall… Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Dominant Brands Consumer Healthcare Brand Ambassadors #1 Condom Brand Kartik Sunny Radhika Aaryan Leone Apte Market Share – 28% #1 Anushka Kajal Srabanti Pre
Slide 14: Exports Business Update
Exports Business Update Revenue from Exports (INR Cr) 1,532 813 469 296 259 FY23 FY24 FY25 Q1FY25 Q1FY26 Revenue growth of 81% YoY primarily due to consolidation of BSV supported by growth in base business Mankind (excl. BSV) has launched 1 product in Q1FY26; taking the total launched products t
Slide 15: Additional Information
ig Mankindii> Serving Life y/ Additional Information
Slide 16: Mankind Pharma at a Glance (FY25)
Mankind Pharma at a Glance (FY25)1 #1 #2 #4 4 Rank in Prescriptions over Rank by volume in Rank by value in Consumer Healthcare brands Market the last eight years2 IPM2 IPM2 ranked #1 in their categories2 Leadership INR 12,207 Cr 87% 49/23 18,000+ Brand families2 worth FY25 Revenue FY25 Domestic Rev
Slide 17: Key Milestones – Disruption led growth
Key Milestones – Disruption led growth 1995 2004 2007-10 2018-19 2020-21 2022 2023 2024 Entered into in- Acquired 100% stake in licensing agreements BSV Limited Successfully listed Commenced Entered chronic Entered Paonta Sahib Launched dedicated specialty Acquired brands with: on NSE and BSE operat
Slide 18: BSV at a Glance (FY25)
BSV at a Glance (FY25) Focused Therapy Presence Differentiated Tech Platforms FY 25 Sales Mix International India 49% 51% Women’s Fertility Critical Recombinant Tech Complex Immunoglobulins Health Care and Niche Biologics Delivery Systems Key Initiatives Recombinant Liposomal Anti-thymocyte Domestic
Slide 19: Consistently Expanding to Specialty and Super Specialty
Consistently Expanding to Specialty and Super Specialty Mass Market Specialty Chronic (Acute/ Chronic / Semi Chronic) (Cardio / Diabeto / CNS) Consumer Healthcare (OTC) BSV - Super Specialty Targeted Medical Practitioners Targeted Medical Practitioners Targeted Medical Practitioners GP CP MD MD DM K
Slide 20: Key Strengths
Key Strengths India revenues contribute 87% of total revenues in FY251 Focus on Focus on Consistent CFO/ EBITDA ratio of ~80% domestic domestic during FY25 business Volume- Best in class business cash growth driven #2 rank by volume in IPM2 conversion by metrics 1 affordability 9 2 Strong 75% of man
Slide 21: Strategy Going Ahead
Strategy Going Ahead Consolidate market share in increased CVM - Deeper penetration in incremental CVM1 (62% in FY21 to 72% in FY25) driven by volume focused growth and scaling up brands. Increasing chronic share - Increasing presence in chronic therapies (Diabetes – Empagliflozin, and Insulin Glarg
Slide 22: Consistently Built and Scaled Brands
Consistently Built and Scaled Brands CAGR Key Brands1 >INR 500 Cr Brand Families FY 21 FY 25 (FY21-25) > INR 500 Crore 0 3 15% > INR 200 Crore 7 11 14% Telmikind – Rs 655 Cr Nurokind – Rs 620 Cr > INR 100 Crore 15 23 13% > INR 50 Crore 36 49 12% Key Brands1 added in FY25 >INR 50 Cr Histafree Brutafl
Slide 23: Consistently Expanding Our Portfolio Towards Specialty Products
Consistently Expanding Our Portfolio Towards Specialty Products Reference Market Brand Launched Market 5 Therapy Area Indication Size (INR Cr) Rationale (Year) – FY25 Year CAGR # (FY22) • Neptaz – In-licensed from Novartis. Strong Revenue and Volume Heart Failure 7251 19% growth. Ranks in the top 5
Slide 24: Financials - Steady Growth Trajectory
1 Financials - Steady Growth Trajectory Revenue (INR Cr) Strong Growth in Domestic Revenue Revenue from Exports (INR Cr) 18% 15% CAGR CAGR 12,207 69% CAGR 10,260 10,675 1,532 8,749 9,447 7,782 8,453 7,595 6,214 6,028 813 296 186 187 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY
Slide 25: Key Performance Highlights
Key Performance Highlights Key Performance Highlights FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Value Growth YoY in IPM (%) 11.3 12.6 12.5 11.1 17.7 10.6 8.5 7.5 Market share by Value in IPM (%) 3.9 4.0 4.1 4.3 4.3 4.4 4.4 4.8 Market Ranking by Value in IPM (x) 4 4 4 4 4 4 4 4 CVM share in total IPM (
Slide 26: Shareholding Pattern
Shareholding Pattern BSE Ticker 543904 1.5% 4.4% 7.3% NSE Symbol MANKIND # of Shares outstanding* 41,27,28,748 14.1% Share Price* 2,319.80 Market Cap. (INR Crore)* 95,745 % Free Float 27.3 72.7% Free Float Market Cap. (INR Cr) 26,138 Industry Pharmaceuticals Promoters FPI & Bodies Corporate Mutual F
Slide 27: Annexures
Annexures • ROCE = (EBIT for the year ) / (Capital employed less cash) o EBIT excludes other income o Capital employed is the sum of total equity, total borrowings, total lease liabilities and deferred tax liabilities (net) less deferred tax assets and Cash. • Adjusted ROCE = (Adjusted EBIT for the
Slide 28: Safe Harbour Statement
Safe Harbour Statement The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goa
Slide 29: Q1 FY26 Earnings Call Details
Q1 FY26 Earnings Call Details Date 1st August, 2025 Time 12:00 PM IST Dial – in Details Universal Access Numbers +91 22 6280 1102 / +91 22 7115 8003 https://services.choruscall.in/DiamondPassRegistration/register?confirm Diamond Pass ationNumber=7759467&linkSecurityString=3933af05ba 28
Slide 30: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Abhishek Agarwal Head - Investor Relations 011 – 46846700 Ext. 3532 Investor.relations@mankindpharma.com